+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Liver Diseases Therapeutics Market - Global Forecast 2026-2030- Product Image
Liver Diseases Therapeutics Market - Global Forecast 2026-2030- Product Image
New

Liver Diseases Therapeutics Market - Global Forecast 2026-2030

  • PDF Icon

    Report

  • 184 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904957
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The liver diseases therapeutics market is evolving rapidly as stakeholders adopt advanced technologies, patient-centric solutions, and new partnership models. Senior decision-makers now face unique opportunities shaped by innovation, regulatory changes, and shifting supply dynamics.

Market Snapshot: Liver Diseases Therapeutics Market Overview

The global liver diseases therapeutics market is forecast to expand robustly from USD 18.76 billion in 2024 to USD 20.26 billion in 2025, with further growth projected to USD 30.00 billion by 2030 at a CAGR of 8.13%. This trajectory highlights greater investments in innovative treatments and enhanced access, in response to the rising prevalence of liver diseases such as hepatitis B, hepatitis C, liver cancers, and nonalcoholic fatty liver disease. Industry collaboration across providers, researchers, and policy-makers is intensifying to address the multifaceted diagnostic and therapeutic challenges associated with these chronic and complex conditions. Heightened awareness and access to state-of-the-art therapies are increasing the momentum for all segments of the market.

Liver Diseases Therapeutics Market Scope & Segmentation

  • Disease Types: Alcoholic liver disease, hepatitis B and C, cholangiocarcinoma, hepatocellular carcinoma, and nonalcoholic fatty liver disease. Each category brings distinct diagnostic and therapeutic complexities, emphasizing the importance of personalization for optimal patient outcomes.
  • Therapy Modalities: Immunotherapies, cell-based and regenerative medicine, gene therapies, microbiome-targeted strategies, and advanced small-molecule drugs represent the mix of modalities, enabling tailored intervention for various pathologies.
  • Administration Routes: Intravenous infusions, oral therapies, and subcutaneous injections are standard routes, each supporting targeted clinical outcomes in line with disease stage and patient preference.
  • Drug Classes: Antifibrotic agents, antiviral categories such as interferons, NS5A/NS5B inhibitors, nucleotide analogues, protease inhibitors, as well as chemotherapeutics, corticosteroids, immunosuppressants, and monoclonal antibodies, together drive the diversity crucial for treating varied progression rates and patient responses.
  • End Users: Clinics, hospitals, home-based care, and digital health-supported models are increasingly prominent. The move toward decentralized and virtual care expands both access and patient convenience.
  • Distribution Channels: Hospital pharmacies, online fulfillment platforms, and retail pharmacies each play a role in effective supply chain management, supporting market reach and optimized delivery.
  • Regional Analysis: The Americas, Europe, Middle East & Africa, and Asia Pacific are evaluated for their innovation climate, policy framework, and healthcare infrastructure, guiding tailored business development and investment approaches.

Key Takeaways for Senior Decision-Makers

  • Precision medicine and digital health advancements are transforming clinical management of liver diseases, supporting more individualized treatment pathways and proactive patient monitoring.
  • Cross-sector collaboration between life sciences, healthcare, and regulatory partners is streamlining product development and improving access for global patient populations.
  • Real-world evidence and adaptive clinical trial designs are enhancing both the efficiency and reliability of therapy validation, strengthening alignment with evolving regulatory standards.
  • Changes in international trade policy and new tariffs are driving increased localization within the pharmaceutical supply chain, fostering domestic investment in production, innovation, and research capacity.
  • Effective market segmentation—including regional, delivery, and care model analysis—enables targeted risk management and supports scalable growth in an increasingly dynamic therapeutic landscape.

Tariff Impact: Navigating Regulatory and Supply Chain Change

With new tariff measures introduced in 2025, the pharmaceutical supply chain, particularly in the United States, faces greater complexity. Cost structures for critical therapeutic ingredients and finished products are being reshaped. As a result, manufacturers are prioritizing regional partnerships and investing in domestic and near-shore production infrastructure. These adjustments are increasing supply chain transparency, improving risk mitigation, and accelerating the establishment of local R&D hubs, with a specific focus on regenerative therapies and advanced delivery models.

Methodology & Data Sources for Market Analysis

This market assessment integrates a combination of secondary and primary research approaches. It includes systematic literature reviews, patent and industry white paper analysis, and over fifty interviews with industry experts, clinicians, and executives. Quality assurance is achieved through triangulation, SWOT analysis, and advisory workshops to capture regional subject matter expertise.

Why This Report Matters: Strategic Value Delivered

  • Supports benchmark-setting for innovation initiatives, helps interpret regulatory shifts, and enables proactive management of supply chain transitions within the liver diseases therapeutics market.
  • Provides actionable segmentation and geographic guidance for effective market entry, product positioning, and optimal partnership identification to support expansion strategies.
  • Consolidates clinical, commercial, and operational insights, facilitating informed resource planning and long-term business growth in the evolving competitive environment.

Conclusion

The market for liver diseases therapeutics is advancing through scientific, collaborative, and business innovation. Organizations that emphasize adaptability and forward-focused strategies will be best placed to realize sustainable commercial growth and long-term differentiation.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2024
3.5. FPNV Positioning Matrix, 2024
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Liver Diseases Therapeutics Market, by Disease Type
8.1. Alcoholic Liver Disease
8.2. Hepatitis B
8.3. Hepatitis C
8.4. Liver Cancer
8.4.1. Cholangiocarcinoma
8.4.2. Hepatocellular Carcinoma
8.5. Non Alcoholic Lever Disease
9. Liver Diseases Therapeutics Market, by Therapy Type
9.1. Biologic Immunotherapies
9.2. Cell-Based & Regenerative Therapy
9.3. Gene Therapy
9.4. Microbiome-Modulating Therapies
9.5. Small-Molecule Drugs
10. Liver Diseases Therapeutics Market, by Route Of Administration
10.1. Intravenous
10.2. Oral
10.3. Subcutaneous
11. Liver Diseases Therapeutics Market, by Drug Class
11.1. Antifibrotic
11.1.1. Pirfenidone
11.1.2. Simtuzumab
11.2. Antivirals
11.2.1. Interferons
11.2.2. NS5A Inhibitors
11.2.3. NS5B Polymerase Inhibitors
11.2.4. Nucleotide/Nucleoside Analogues
11.2.5. Protease Inhibitors
11.3. Chemotherapeutic
11.4. Corticosteroids
11.5. Immunosuppressants
11.6. Monoclonal Antibody
12. Liver Diseases Therapeutics Market, by End User
12.1. Clinic
12.2. Home Care Settings
12.3. Hospital
13. Liver Diseases Therapeutics Market, by Distribution Channel
13.1. Hospital Pharmacy
13.2. Online Pharmacy
13.3. Retail Pharmacy
14. Liver Diseases Therapeutics Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Liver Diseases Therapeutics Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Liver Diseases Therapeutics Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Liver Diseases Therapeutics Market
18. China Liver Diseases Therapeutics Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2024
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2024
19.3. Product Portfolio Analysis, 2024
19.4. Benchmarking Analysis, 2024
19.5. AbbVie Inc.
19.6. Alnylam Pharmaceuticals, Inc.
19.7. Astellas Pharma Inc.
19.8. AstraZeneca PLC
19.9. Bristol-Myers Squibb Company
19.10. C. H. Boehringer Sohn AG & Co. KG
19.11. Eli Lilly and Company
19.12. F. Hoffmann-La Roche Ltd.
19.13. Genfit S.A.
19.14. Gilead Sciences, Inc.
19.15. GlaxoSmithKline plc
19.16. Intercept Pharmaceuticals, Inc. by Alfasigma S.p.A.
19.17. Johnson & Johnson Services Inc.
19.18. Merck & Co., Inc.
19.19. Moderna, Inc.
19.20. Novartis AG
19.21. Pfizer Inc.
19.22. Sanofi SA
19.23. Takeda Pharmaceutical Company Limited
19.24. Vertex Pharmaceuticals Incorporated
List of Figures
FIGURE 1. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 2. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 3. GLOBAL LIVER DISEASES THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 4. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 14. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
List of Tables
TABLE 1. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 2. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 3. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY GROUP, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY GROUP, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY GROUP, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY GROUP, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY GROUP, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NON ALCOHOLIC LEVER DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NON ALCOHOLIC LEVER DISEASE, BY GROUP, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NON ALCOHOLIC LEVER DISEASE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGIC IMMUNOTHERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGIC IMMUNOTHERAPIES, BY GROUP, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGIC IMMUNOTHERAPIES, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CELL-BASED & REGENERATIVE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CELL-BASED & REGENERATIVE THERAPY, BY GROUP, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CELL-BASED & REGENERATIVE THERAPY, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY MICROBIOME-MODULATING THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY MICROBIOME-MODULATING THERAPIES, BY GROUP, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY MICROBIOME-MODULATING THERAPIES, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SMALL-MOLECULE DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SMALL-MOLECULE DRUGS, BY GROUP, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SMALL-MOLECULE DRUGS, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, BY GROUP, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY PIRFENIDONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY PIRFENIDONE, BY GROUP, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY PIRFENIDONE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SIMTUZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SIMTUZUMAB, BY GROUP, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SIMTUZUMAB, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY GROUP, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NS5A INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NS5A INHIBITORS, BY GROUP, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NS5A INHIBITORS, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY GROUP, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE/NUCLEOSIDE ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE/NUCLEOSIDE ANALOGUES, BY GROUP, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE/NUCLEOSIDE ANALOGUES, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPEUTIC, BY GROUP, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPEUTIC, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 84. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 85. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2030 (USD MILLION)
TABLE 86. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 87. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 88. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2030 (USD MILLION)
TABLE 89. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 90. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
TABLE 91. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2030 (USD MILLION)
TABLE 92. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 93. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 94. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 95. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2030 (USD MILLION)
TABLE 96. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 97. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 98. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2030 (USD MILLION)
TABLE 99. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 100. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 101. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2030 (USD MILLION)
TABLE 102. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 103. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 105. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2030 (USD MILLION)
TABLE 106. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 107. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 108. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2030 (USD MILLION)
TABLE 109. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 110. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 111. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2030 (USD MILLION)
TABLE 112. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 113. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 114. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
TABLE 115. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 116. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
TABLE 117. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 118. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 120. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
TABLE 121. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 122. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 125. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 126. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
TABLE 127. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 128. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 130. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
TABLE 131. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 132. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 135. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 136. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
TABLE 137. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 138. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 140. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
TABLE 141. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 142. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 143. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 155. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 156. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
TABLE 157. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 158. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 159. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 160. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
TABLE 161. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 162. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 165. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 166. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
TABLE 167. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 168. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 170. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
TABLE 171. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 172. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 175. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 176. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
TABLE 177. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 178. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 180. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
TABLE 181. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 182. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 185. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 186. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
TABLE 187. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 188. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 190. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
TABLE 191. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 192. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 193. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
TABLE 195. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 196. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 197. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
TABLE 198. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 199. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 200. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 201. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
TABLE 202. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 203. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 205. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 206. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 207. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
TABLE 208. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 209. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 211. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
TABLE 212. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 213. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 215. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 216. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 217. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
TABLE 218. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 219. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 221. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
TABLE 222. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 223. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 225. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 226. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 227. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
TABLE 228. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 229. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 231. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
TABLE 232. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 233. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 236. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 237. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
TABLE 238. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 239. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 240. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 241. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
TABLE 242. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 243. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 244. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 246. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 247. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
TABLE 248. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 249. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 250. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 251. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
TABLE 252. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 253. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 255. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 256. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 257. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 258. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
TABLE 259. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 260. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 261. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 262. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
TABLE 263. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 264. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 266. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 267. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 268. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
TABLE 269. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 270. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 271. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 272. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
TABLE 273. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 274. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 275. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)

Companies Mentioned

The key companies profiled in this Liver Diseases Therapeutics market report include:
  • AbbVie Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • C. H. Boehringer Sohn AG & Co. KG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genfit S.A.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Intercept Pharmaceuticals, Inc. by Alfasigma S.p.A.
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated

Table Information

Report AttributeDetails
No. of Pages184
PublishedJanuary 2026
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 20.26 Billion
Forecasted Market Value ( USD ) by 2030 $ 30 Billion
Compound Annual Growth Rate8.1%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Alcoholic Liver Disease Treatment Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Alcoholic Liver Disease Treatment Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Liver Disease Therapeutic Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033 - Product Image

Liver Disease Therapeutic Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033

  • Report
  • 200 Pages
  • Global
From
Liver Disease Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034 - Product Image

Liver Disease Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

  • Report
  • 130 Pages
  • Global
From
Liver Disease Treatment Market Size Analysis Report - Market Share, Forecast Trends and Outlook (2025-2034) - Product Image

Liver Disease Treatment Market Size Analysis Report - Market Share, Forecast Trends and Outlook (2025-2034)

  • Report
  • 400 Pages
  • Global
From
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Insight, 2025 - Product Image

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Insight, 2025

  • Clinical Trials
  • 240 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.